ArticleBiology direct2026
SERPINH1 expression represents a reliable biomarker of human breast cancer aggressiveness.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExtracellular matrix (ECM) remodeling is a central driver of breast cancer progression, invasion, and metastatic dissemination. Heat shock protein 47 (HSP47), encoded by SERPINH1, is a collagen-specific molecular chaperone essential for proper collagen folding and secretion, but its clinical and biological relevance in human breast cancer remains incompletely defined.
methodsWe applied an integrated multi-omics approach combining RNA sequencing, quantitative proteomics, immunohistochemistry, and spatial single-cell transcriptomics to analyze SERPINH1 expression in 21 human breast carcinomas. Internal cohort and public datasets were investigated to assess expression patterns, pathway associations, and clinical relevance across breast cancer patients.
resultsSERPINH1 expression strongly correlated with key ECM-remodeling genes, including COL1A1, CTGF, and DDR2, and showed robust concordance with HSP47 protein abundance. High SERPINH1 levels were tightly linked to epithelial-mesenchymal transition (EMT) programs, including ZEB1-, MMP2-, and TGF-β-driven signaling, while displaying minimal association with immune-checkpoint pathways or immune-cell infiltration. Spatial and single-cell analyses revealed enrichment of SERPINH1 in cancer-associated fibroblasts and malignant epithelial cells. Clinically, SERPINH1 expression increased from normal breast tissue to primary tumours and metastatic lesions, was highest in advanced-stage disease, and predicted reduced overall survival, particularly in luminal B breast cancer. Notably, high SERPINH1 expression was associated with improved pathological response to chemotherapy.
conclusionsThese findings identify SERPINH1 as a marker of ECM-driven tumour aggressiveness and stromal reprogramming in breast cancer. By linking collagen homeostasis, EMT, and TGF-β signaling to adverse clinical outcomes, the SERPINH1-HSP47 axis emerges as a promising prognostic biomarker and a tractable therapeutic target in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.